| Background: Pancreatic cancer is a rapidly fatal disease with a 5-year survival <5%. Surgical resection offers the only potentially curative treatment. The poor prognosis of pancreatic cancer is due to both its metastasis-prone and therapy-resistant nature. Thus in conjunction to surgery or chemotherapy, radiotherapy may achieve better clinical results. However, radiotherapy response varies individually, with clinical reports of radiation resistance. Published reports state an existing relationship between radio-sensitivity and gene expression and regulation, but such reports lack coherence and consistency, since the same gene mentioned to be responsible for radiosensitivity has also been reported to have opposite results, and there yet lacks sufficient evidence regarding the study of genetic promotion of radiation in the treatment and relationship to pancreatic cancer. DNA microarrays have become a standard tool for several applications in molecular biology and provide a way to monitor the expression of thousands of genes in a single assay.Purpose: To study the genetic processes and the molecular mechanism of radioresistance in pancreatic cancer, and to identify the novel radioresistance-associated genes. We investigated the gene expression profile among SW1990, SW1990/R, ASPC and ASPC/R cells by microarray analyses.Our research objective through laboratory research was to provide experimental evidence for clinical pancreatic cancer radiotherapy.Methods:1. The radio-sensitivity of SW1990, SW1990/R, ASPC and ASPC/R cells were tested using a clonogenic assay.2. Gene expression profiles of SW1990, SW1990/R, ASPC and ASPC/R cells were screened using oligonucleotide microarray (Affymetrix HG U133 2.0plus) which contained approximately 38000 human genes.3. The results of microarray were analyzed by Genechip (?) Operating System1.2 and Genespring v7.2, Netaffy (http://www.affymetrix.com) and NCBI... |
PDF Full Text Request